DOW JONES27,960.80-1031.61 -3.56%
S&P 5003,225.89-111.86 -3.35%
NASDAQ9,221.28-355.31 -3.71%

BMO Capital Maintains Outperform on Aquestive Therapeutics, Lowers Price Target to $18

BMO Capital maintains Aquestive Therapeutics (NASDAQ:AQST) with a Outperform and lowers the price target from $19 to $18.

Benzinga · 01/13/2020 15:13

BMO Capital maintains Aquestive Therapeutics (NASDAQ:AQST) with a Outperform and lowers the price target from $19 to $18.